MiR-128-2 inhibits common lymphoid progenitors from developing into progenitor B cells

Yi Yang,Jie Xu,Huo Chen,X. Fei,Yuxu Tang,Yunqiu Yan,Huimin Zhang,Jinping Zhang
DOI: https://doi.org/10.18632/oncotarget.8161
2016-03-17
Oncotarget
Abstract:A considerable number of studies revealed that B cell development is finely regulated by transcription factors (TFs). Recent studies suggested that TFs are coordinated with microRNAs to control the development of B cells in numerous checkpoints. In the present study, we first found that miR-128-2 was differentially expressed in various immune organs and immunocytes. B cell development was inhibited in miR-128-2-overexpressed chimera and transgenic (TG) mice in bone marrow with decreased preproB, preB, proB, immature B, and recirculating B cells, as well as increased common lymphoid progenitors (CLPs). Further experiments showed that the apoptosis of CLP decreased, but proliferation was not altered in miR-128-2-overexpressed mice. Extensive studies suggested that the inhibition of apoptosis of CLP may be caused by miR-128-2 targeting A2B and MALT1, thereby increasing the phosphorylation of ERK and P38 MAPK. Such findings have prompted future investigations on the function of miR-128-2 in lymph genesis.
What problem does this paper attempt to address?